Washout period for immune-modifying drugs before natalizumab therapy.
Ilanjian
Hilda
H
Shane
Rita
R
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D004347:Drug Interactions; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D008657:Metabolic Clearance Rate; D009103:Multiple Sclerosis / Q000188:drug therapy; D000069442:Natalizumab; D012308:Risk Management; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069442:Natalizumab